Trending...
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
EAST RUTHERFORD, N.J., Sept. 19, 2024 ~ Cambrex, a global contract development and manufacturing organization (CDMO), has recently announced a breakthrough in peptide synthesis technology. The company's subsidiary, Snapdragon Chemistry, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology that eliminates the need for specialized solid-phase reactors.
This innovative LPPS technology utilizes traditional active pharmaceutical ingredient (API) batch reactors and continuous flow, significantly reducing solvent demand and excess reagents compared to standard solid-state peptide synthesis processes. This not only makes the process more cost-efficient but also more environmentally sustainable.
Dr. Matt Bio, Chief Scientific Officer at Cambrex, stated that the company has been investing in research and development of complex synthetics for several years with the goal of reducing economic and environmental impacts in peptide and oligonucleotide manufacturing. He added that their new LPPS technology offers a more efficient and sustainable solution compared to traditional methods.
More on Jersey Desk
The LPPS technology can support peptides up to 12 residues long, while larger peptides can be assembled using a convergent fragment coupling approach in liquid phase. This allows for scalability similar to traditional small molecules.
In addition to LPPS, Cambrex has also developed unique capabilities in peptide and protein crystallization. They have a screening platform specifically designed for discovering crystalline forms of peptides and proteins. Crystallization can improve product quality and stability while reducing the need for time-consuming preparative chromatography and lyophilization.
Thomas Loewald, CEO at Cambrex, emphasized the importance of providing industry-leading solutions for developing and scaling peptide-based therapies. He stated that their continued investment in R&D across complex synthetic modalities will include further technology development for peptides as well as research on the application of artificial intelligence in optimizing oligonucleotide processes.
Cambrex's new LPPS technology is expected to have a significant impact on the pharmaceutical industry by offering a more efficient and sustainable method for synthesizing peptides. With their continued investment in research and development, the company is poised to remain a leader in complex synthetic modalities.
This innovative LPPS technology utilizes traditional active pharmaceutical ingredient (API) batch reactors and continuous flow, significantly reducing solvent demand and excess reagents compared to standard solid-state peptide synthesis processes. This not only makes the process more cost-efficient but also more environmentally sustainable.
Dr. Matt Bio, Chief Scientific Officer at Cambrex, stated that the company has been investing in research and development of complex synthetics for several years with the goal of reducing economic and environmental impacts in peptide and oligonucleotide manufacturing. He added that their new LPPS technology offers a more efficient and sustainable solution compared to traditional methods.
More on Jersey Desk
- $34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thinner, Less Problematic Than Warfrain: $CVKD
- Pikmykid Launches $100,000 School Safety Grant Giveaway to Support K–12 Schools Across the U.S
- Slotozilla Data Report: Unveiling 2024's Gaming Statistics
- BK Flooring Releases Their Top Reasons to Upgrade Kitchen Tile Flooring in 2025
- The OpenSSL Corporation and the OpenSSL Foundation Certify Results of Technical Advisory Committee Elections
The LPPS technology can support peptides up to 12 residues long, while larger peptides can be assembled using a convergent fragment coupling approach in liquid phase. This allows for scalability similar to traditional small molecules.
In addition to LPPS, Cambrex has also developed unique capabilities in peptide and protein crystallization. They have a screening platform specifically designed for discovering crystalline forms of peptides and proteins. Crystallization can improve product quality and stability while reducing the need for time-consuming preparative chromatography and lyophilization.
Thomas Loewald, CEO at Cambrex, emphasized the importance of providing industry-leading solutions for developing and scaling peptide-based therapies. He stated that their continued investment in R&D across complex synthetic modalities will include further technology development for peptides as well as research on the application of artificial intelligence in optimizing oligonucleotide processes.
Cambrex's new LPPS technology is expected to have a significant impact on the pharmaceutical industry by offering a more efficient and sustainable method for synthesizing peptides. With their continued investment in research and development, the company is poised to remain a leader in complex synthetic modalities.
Filed Under: Business
0 Comments
Latest on Jersey Desk
- 2025 AAHFN CEC Symposium - Facing the Challenges: Managing Hyperkalemia in Heart Failure Patients While Maintaining RAASi Therapy
- lotus823 & CMI Corporation Announces Strategic Partnership
- RWA Infra Development L.L.C. announces the $RWAID token. "$RWAID tokenizing infrastructure for the masses."
- The Harlem Globetrotters Sports Residency Returns To American Dream July 2025 For 9 Consecutive Days
- Understanding the Payment Card Interchange Fee Settlement
- Mental Health Awareness Month—Tennessee Enacts Psychotropic Testing Law
- Federal Independent Contractor Rule Update
- Be Prepared for the Qualitative and Quantitative Effects of Tariffs: How Businesses Can Navigate Potential Disruption in Finances and Production
- New Measures on Small Business Administration Loans
- LBI's Internationally Celebrated Festival Rolls June 4-8
- Bold Beauty Project UCLA Edition Photography Exhibition on May 18
- Genuine Hospitality, LLC Selected to Operate Claridge House Chicago Gold Coast
- Lamar Odom Issues Public Challenge to X Platform Over Censorship of His Anti-Addiction Crypto Campaign
- Conte Dentistry Offers Customized Sleep Apnea Treatment in Red Bank, NJ
- PBK Miner completes $80 million Series B financing to support AI cloud mining and increase user investment return by 25%
- Asset-Backed Green Crypto: Fueling the Trillion-Dollar Revolution
- The Susquehanna Mine Train now open for it;s 20th Season
- Fairmint Introduces First Fully Onchain and Open Cap Table Infrastructure
- Vortex Brands Begins Gold Purchases Under New Joint Venture with Dubai-Based Partner
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3